Passa al contenuto
Merck
Tutte le immagini(1)

Documenti

M1850000

Metronidazole

European Pharmacopoeia (EP) Reference Standard

Sinonimo/i:

2-Methyl-5-nitroimidazole-1-ethanol

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali
Tutte le immagini(1)

About This Item

Formula empirica (notazione di Hill):
C6H9N3O3
Numero CAS:
443-48-1
Peso molecolare:
171.15
Beilstein:
611683
Numero MDL:
MFCD00009750
Codice UNSPSC:
41116107
ID PubChem:
329817897
NACRES:
NA.24

Grado

pharmaceutical primary standard

Famiglia di API

metronidazole

Produttore/marchio commerciale

EDQM

Punto di fusione

159-161 °C (lit.)

applicazioni

pharmaceutical (small molecule)

Formato

neat

Temperatura di conservazione

2-8°C

Stringa SMILE

CC1=NC=C([N+]([O-])=O)N1CCO

InChI

1S/C6H9N3O3/c1-5-7-4-6(9(11)12)8(5)2-3-10/h4,10H,2-3H2,1H3
VAOCPAMSLUNLGC-UHFFFAOYSA-N

Cerchi prodotti simili? Visita Guida al confronto tra prodotti

Categorie correlate

Descrizione generale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Applicazioni

Metronidazole EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Confezionamento

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Altre note

Sales restrictions may apply.

Pittogrammi

Health hazard
GHS08

Avvertenze

Danger

Indicazioni di pericolo

H340,H350,H373

Classi di pericolo

Carc. 1B - Muta. 1B - STOT RE 2

Codice della classe di stoccaggio

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

Classe di pericolosità dell'acqua (WGK)

WGK 3

Punto d’infiammabilità (°F)

Not applicable

Punto d’infiammabilità (°C)

Not applicable

Choose from one of the most recent versions:

Certificati d'analisi (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Servizio Clienti

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

I clienti hanno visto anche

Slide 1 of 5

1 of 5

Clarithromycin ≥95% (HPLC)

Sigma-Aldrich

C9742

Clarithromycin

USP

USP

1709007

Vancomycin hydrochloride

Neomycin trisulfate salt hydrate powder

Sigma-Aldrich

N1876

Neomycin trisulfate salt hydrate

Supelco

Supelco

PHR1491

Neomycin Sulfate

Vancomycin hydrochloride European Pharmacopoeia (EP) Reference Standard

V0045000

Vancomycin hydrochloride

Sonja Löfmark et al.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 50 Suppl 1, S16-S23 (2010-01-14)
Metronidazole has been used for the treatment of infections for >45 years and is still successfully used for the treatment of trichomoniasis, amoebiasis, and giardiasis. Anaerobic bacterial infections caused by Bacteroides species, fusobacteria, and clostridia respond favorably to metronidazole therapy.
Konstantinos Z Vardakas et al.
International journal of antimicrobial agents, 40(1), 1-8 (2012-03-09)
The objective of this review was to evaluate the frequency of treatment failure and recurrence of Clostridium difficile infection (CDI) following treatment with vancomycin or metronidazole in recently performed studies (last 10 years). Searches in PubMed and Scopus were performed
Fabrizio Sgolastra et al.
Journal of periodontology, 83(6), 731-743 (2011-11-05)
The systemic use of combined amoxicillin and metronidazole (AMX/MET) as an adjunctive treatment to full-mouth scaling and root planing (FMSRP) has been proposed for the treatment of generalized aggressive periodontitis; however, its effectiveness and clinical safety remain to be defined.
David B Stewart et al.
Annals of surgery, 260(2), 299-304 (2014-01-01)
To identify Clostridium difficile genotypes, which are associated with recurrent C difficile infection (RCDI). Reliable bacterial genetic factors predicting RCDI are currently lacking. Inpatients and outpatients 18 years or older treated at our institution for C difficile infection (CDI) of
Michael John Aldape et al.
The Journal of antimicrobial chemotherapy, 70(1), 153-159 (2014-08-26)
Clostridium difficile infection (CDI) is mediated by potent extracellular toxins and is spread largely via bacterial spores. We and others have shown that some antibiotics stimulate C. difficile toxin production in a strain-specific manner; however, the effects of newer anti-C.
Visualizza tutti i documenti correlati

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.